Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

Exclusion Criteria

• •Patients who have previously received PD-1/PD-L1 antibody treatment;
• •Respiratory syndrome caused by pleural effusion or ascites (according to NCICTCAE classification ≥ grade 2 dyspnea;
• •Patients with brain metastases accompanied by symptoms or symptom control time less than 2 months;
• •Has experienced or currently suffers from other malignant tumors within 5 years;
• •Within the first 4 weeks of grouping or during the medication period of this study, it is planned to undergo systemic anti-tumor therapy, including cytotoxic therapy and targeted drug therapy. Received radiotherapy within 4 weeks prior to grouping;
• •Patients with any severe and/or uncontrolled diseases
• •Received significant surgical treatment, open biopsy, or obvious traumatic injury within 28 days prior to grouping;
• •Patients with any signs of bleeding or medical history, regardless of severity; Within the first 4 weeks of grouping, patients with any bleeding or bleeding events ≥ CTCAE level 3, with unhealed wounds, ulcers, or fractures;
• •Individuals who have experienced arterial/venous thrombosis events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis, and pulmonary embolism;
• •Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
• •Participated in clinical trials of other anti-tumor drugs within four weeks;
• •According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study;